We are investigating Becton, Dickinson and Company (BDX) (“Becton” or the “Company”) for potential violations of the federal securities laws.
On February 6, 2020, Becton lowered its fiscal 2020 guidance, announcing that the Company expected revenue to increase by only 1.5% to 2.5%, “to reflect the impact of the remediation effort and anticipated loss of sales of the Alaris infusion system.” According to Becton, the software remediation plan for the Company’s Alaris system “will require additional regulatory filings,” and existing customers would have “access to the Alaris System under medical necessity.” Becton further disclosed that it had recorded a $59 million charge in connection with a voluntary recall of certain Alaris pumps. On this news, Becton’s stock price fell $33.74 per share, or 11.8%, to close at $252.25 per share on February 6, 2020.